share_log

CardioComm Solutions Awarded Canadian Space Agency Contract for Design of Next Generation Connected Care Medical Module Prototype

CardioComm Solutions Awarded Canadian Space Agency Contract for Design of Next Generation Connected Care Medical Module Prototype

CardioComm Solutions榮獲加拿大宇航局合同,設計下一代連接護理醫療模塊原型。
newsfile ·  10/17 01:29

GEMS(TM) C2M2 will Detect, Diagnose, Treat and Monitor Health Conditions for Use in Space Missions and in Remote Communities on Earth.

GEMS(TM) C2M2將用於探測、診斷、治療和監測太空任務和地球偏遠社區中使用的健康狀況。

Toronto, Ontario--(Newsfile Corp. - October 16, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider and pioneer of Remote Patient Monitoring (RPM) solutions for direct-to-consumer heart monitoring and prescribed ambulatory electrocardiogram ("ECG") software and hardware solutions, is pleased to announce it has been awarded, through a competitive process, up to $150,000 in funding from the Canadian Space Agency (CSA) for design of the next generation prototype for the CSA's Connected Care Medical Module (C2M2)1.

安大略省多倫多--(Newsfile corp. - 2024年10月16日)- CardioComm Solutions,Inc.(TSXV: EKG)("CardioComm" 或 "公司"),一家全球醫療服務提供商,也是遠程患者監控(RPM)解決方案的先驅,致力於爲直接消費者提供心臟監測和處方服務的動態心電圖軟件和硬件解決方案,非常高興地宣佈已獲得加拿大空間局通過競爭過程評選的設計下代原型的最高15萬美元資助。

The CSA C2M2 is a highly innovative, AI-supported system designed to address the unique challenges of medical care in isolated environments, whether in space or on Earth. This dual use, both in space and for terrestrial applications, makes the C2M2 a critical development for improving healthcare accessibility and reliability in environments where traditional medical care is hard to access.

CSA C2M2是一個高度創新的人工智能支持系統,旨在解決在孤立環境中醫療護理的獨特挑戰,無論是在太空還是地球上。這種太空和地面應用的雙重用途,使得C2M2對改善醫療保健可獲得性和可靠性在傳統醫療護理難以獲得的環境中至關重要。

The CardioComm prototype, GEMS C2M2, will build on CardioComm's experience in the development of innovative and device-agnostic RPM software platforms for cardiac medical monitoring. The Company recently expanded its cardiac RPM technologies through its innovative Body-by-GEMS program, which provides for a device-agnostic solution for monitoring of multiple bio-signals including ECG, temperature, SpO2, blood pressure and heart rate. The CSA C2M2 funding will facilitate the Company's expansion into a broader range of near real-time RPM of multiple bio-signals including development of protocols for autonomous differential diagnosis, treatment and follow-up monitoring of patients where limited access to medical services exists.

CardioComm原型GEMS C2M2將借鑑CardioComm在心臟醫療監測的創新和硬件不可知設計方面的經驗。公司最近通過其創新的Body-by-GEMS項目擴展了其心臟RPM技術,該項目爲監測多種生物信號(包括心電圖、體溫、SpO2、血壓和心率)提供了一種硬件不可知的解決方案。CSA C2M2資助將促進公司在多種生物信號的近實時RPM方面擴展業務,包括開發自主差異診斷、治療和後續監測協議,用於病人的醫療服務有限的情況。

The key components CardioComm will develop in their design (GEMS C2M2) are:

CardioComm在其設計中將開發的關鍵元件(GEMS C2M2)爲:

Artificial Intelligence (AI) Supported Computer System:

人工智能(AI)支持計算機系統:

  • Facilitates incorporation and interconnection of medical technologies: GEMS C2M2 will be device-agnostic and will integrate a wide array of medical devices and technologies, ensuring seamless communication between them, through standardized protocols.
  • Plug-and-play architecture: GEMS C2M2 will allow for flexible configurations of medical technologies, enabling customization based on the needs of the user, the environment, or mission. This would be critical in rapidly changing or evolving medical situations in space.
  • 促進醫療技術的整合和互連:GEMS C2M2將是設備不可知的,將整合各種醫療設備和技術,在它們之間確保無縫通信,通過標準化協議。
  • 插拔式架構:GEMS C2M2將允許醫療技術的靈活配置,根據用戶、環境或任務的需求進行定製。這在太空中迅速變化或演變的醫療情況中至關重要。

Autonomy in Healthcare:

醫療保健中的自主權:

  • End-user capacity for autonomous management: GEMS C2M2 will be designed to empower non-medical personnel, such as astronauts, to handle various health conditions independently. This would include everything from monitoring vital signs, diagnosing potential issues, to initiating treatment or providing recommendations for health management.
  • Detection, diagnosis, treatment, and monitoring: The GEMS C2M2 AI will assist in each of these stages, offering decision support, and where appropriate, automating the medical process, reducing the need for human intervention.
  • 終端用戶自主管理能力:GEMS C2M2將被設計爲賦予非醫學人員(如宇航員)處理各種健康狀況的能力。這將包括從監測生命體徵,診斷潛在問題,到啓動治療或提供建議進行健康管理。
  • 檢測、診斷、治療和監測:GEMS C2M2人工智能將在這些階段提供協助,提供決策支持,並在適當時自動化醫療流程,減少人爲干預的需要。

Space Exploration:

太空探索:

  • Self-reliance for long-duration space missions: For Moon or Mars missions, where immediate access to medical professionals is impossible, astronauts will rely on the selected CSA system to manage both acute and long-term health conditions. The system's ability to work autonomously is a crucial requirement for mission success and crew safety.
  • 長時間太空任務的自給自足:對於月球或火星任務,無法立即接觸醫療專業人員的情況下,宇航員將依賴所選的CSA系統來管理急性和長期健康狀況。系統的自主工作能力對於任務成功和機組安全至關重要。

Application for Remote Communities:

應用於偏遠社區:

  • Serving Canadians in remote areas: While designed for space, the GEMS C2M2's application will be developed to improve healthcare for people living in isolated regions of Canada where access to healthcare is limited. The GEMS C2M2 AI-supported system will be developed to provide a similar level of autonomy and health management support, reducing the burden on healthcare infrastructure and improving patient outcomes.
  • 爲偏遠地區的加拿大人服務:雖然設計用於太空,但GEMS C2M2的應用將被開發用於改善加拿大偏遠地區居民的醫療保健,那裏的醫療資源有限。GEMS C2M2人工智能支持的系統將被開發爲提供類似的自主權和健康管理支持,減輕醫療基礎設施的負擔,改善患者預後。

Funding will be provided following presentation of the prototype design, which is scheduled for October 28, 2024. The CSA will select up to three companies funded for this design phase to proceed with funding of up to $650,000 for the development of a prototype C2M2 solution. The focus of the prototypes will be integrating medical software and technologies as a path for their potential deployment in space.

根據計劃於2024年10月28日展示的原型設計,將提供資金支持。 CSA將選擇最多三家公司進行資助,用於開發最高可達65萬美元的原型C2M2解決方案。原型的重點將是整合醫療軟件和技術,作爲它們在太空潛在部署的途徑。

To learn more about CardioComm's products and for further updates please visit the Company's websites at .

要了解更多關於CardioComm產品以及進一步更新,請訪問公司網站。

About CardioComm Solutions

關於CardioComm Solutions

Toronto-based CardioComm Solutions' ("CardioComm" and the "Company") proprietary technologies are used remote patient monitoring (RPM). CardioComm's core products are used for remote recording, viewing, analyzing, reporting and storing of electrocardiograms for diagnosis and management of cardiac patients. CardioComm also became the first company to enter into the direct to consumer, personalized ECG monitoring market. With its suite of medically credible heart monitoring solutions for the medical and consumer markets, CardioComm continues to be a leader in ECG management technologies. CardioComm will be expanding use of its RPM and telemedicine technologies into the sports, health and wellness. Such efforts will facilitate the introduction of new wearable devices such as Smartwatches, chest straps, smart garments and patches that will collect additional monitored bio-signs and multiple ECG leads/channels options (1, 3 and 12 lead). Additionally, CardioComm will expand its HeartCheck branded direct to consumer solutions to include other bio-sign monitoring devices compatible with CardioComm's technologies. The Company's goal is to provide patients and caregivers with opportunities to consult and collaborate with specialists no matter the location, improving patient care and reducing costs. CardioComm has earned the ISO 13485 MDSAP and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

總部位於多倫多的CardioComm Solutions ("CardioComm"和"公司")專有技術用於遠程患者監測(RPM)。 CardioComm的核心產品用於遠程記錄、查看、分析、報告和存儲心電圖以診斷和管理心臟患者。CardioComm還成爲首家進入面向消費者的個性化心電圖監測市場的公司。憑藉其一套醫學可信賴的心臟監測方案,適用於醫療和消費市場,CardioComm繼續引領ECG管理技術。 CardioComm將其RPm和遠程醫療技術擴展到體育、健康和健康領域。這些努力將推動新的可穿戴設備的推出,如智能手錶、胸帶、智能服裝和貼片,這些設備將收集其他監測的生物標誌和多通道ECG選項(1、3和12導聯)。此外,CardioComm將擴展其HeartCheck品牌的面向消費者的解決方案,以包括與CardioComm技術兼容的其他生物標誌監測設備。公司的目標是爲患者和護理人員提供與專家協商和合作的機會,無論所在地,以改善患者護理並降低成本。 CardioComm已獲得ISO 13485 MDSAP和ISO 27001認證,符合HIPAA合規要求,持有美國(FDA)和加拿大(Health Canada)的醫療器械許可和銷售許可。

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

欲了解更多信息請聯繫:
Etienne Grima,首席執行官
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

Forward-looking statements

前瞻性聲明

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

本公告可能包含關於CardioComm Solutions財務狀況、經營業績和業務以及CardioComm Solutions關於這些事項的計劃和目標的某些前瞻性陳述和前瞻性信息。這些陳述和信息反映了管理層當前的信念,基於目前管理層可獲得的信息。由於它們涉及將來發生的事件並取決於將來發生的環境,前瞻性陳述和前瞻性信息的性質使其涉及風險和不確定性,並且有許多因素可能導致實際結果和發展與這些前瞻性陳述和前瞻性信息所暗示的結果有重大差異。

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

在評估這些陳述時,讀者不應過分依賴前瞻性陳述和前瞻性信息。公司不會對本發佈中包含的前瞻性陳述和前瞻性信息承擔任何更新的義務,除了適用法律(包括但不限於51-102國家工具(持續披露義務)第5.8(2)節)要求的情況之外。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX創業公司交易所及其監管服務提供者(如TSX創業公司政策所定義)均不承擔本發佈信息充分性或準確性的責任。

1

1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論